| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Fulton Co. Emergency Medical Association, Inc. is a Canton, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Perimeter Institute for Theoretical Physics is a basic research centre dedicated to exploring the world around us at its most fundamental level.
OmnisSYS is a Greenville, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Sanare is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.